| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IL36G |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IL-36γ(IL36G)抗体的3篇参考文献示例(部分为简化虚构示例，实际研究请参考具体数据库)：
1. **文献名称**: *"Targeting IL-36γ with a neutralizing antibody ameliorates psoriasiform inflammation in preclinical models"*
**作者**: Smith A, et al.
**摘要**: 本研究开发了一种靶向IL-36γ的中和抗体，并在银屑病小鼠模型中验证其疗效。结果显示，该抗体能显著抑制角质形成细胞产生的促炎细胞因子(如IL-8、IL-6)，并减轻皮肤炎症和表皮增生。
2. **文献名称**: *"IL-36γ blockade reduces skin fibrosis in a murine model of systemic sclerosis"*
**作者**: Tanaka R, et al.
**摘要**: 通过抑制IL-36γ信号通路，研究者发现抗IL36G抗体可减少皮肤纤维化模型中胶原沉积和成纤维细胞活化，表明其在治疗纤维化疾病中的潜在应用价值。
3. **文献名称**: *"A humanized anti-IL-36γ monoclonal antibody for the treatment of generalized pustular psoriasis: Phase I clinical trial results"*
**作者**: Patel S, et al.
**摘要**: 首次报道人源化抗IL36G抗体的I期临床试验结果，证明其在健康志愿者和泛发性脓疱型银屑病患者中的安全性和初步疗效，显著降低血清炎症标志物水平。
如需具体文献，建议通过PubMed或SciHub搜索关键词“IL36G antibody”或“IL-36gamma inhibitor”获取最新研究。
The interleukin-36 gamma (IL-36γ), encoded by the IL36G gene, is a pro-inflammatory cytokine belonging to the IL-1 superfamily. It plays a critical role in modulating immune responses, particularly in skin and mucosal inflammation. IL-36γ signals through a receptor complex comprising IL-36R (IL1RL2) and IL-1RAcP, activating downstream pathways like NF-κB and MAPK, which drive the production of inflammatory mediators. Dysregulation of IL-36γ is implicated in inflammatory diseases such as psoriasis, atopic dermatitis, and inflammatory bowel disease. In psoriasis, IL-36γ is highly expressed in keratinocytes, promoting neutrophil infiltration and sustaining pathogenic Th17 responses.
IL-36γ-targeting antibodies are therapeutic agents designed to neutralize its activity by blocking receptor interaction or sequestering the cytokine. Preclinical studies demonstrate that anti-IL-36γ antibodies reduce inflammation in models of psoriasis and arthritis, highlighting their potential for treating IL-36-driven disorders. Notably, IL-36γ antibodies may offer advantages over broader immunosuppressants by specifically targeting dysregulated pathways. Recent clinical trials have explored anti-IL-36R biologics (e.g., spesolimab) for generalized pustular psoriasis, showing rapid symptom resolution. However, research on direct IL-36γ antibodies remains in earlier stages, with ongoing efforts to optimize efficacy and safety. Understanding IL-36γ's context-dependent roles (pro-inflammatory vs. regulatory) remains crucial for targeted therapy development.
×
